Rosen Law Firm Takes Action for Investors of ADMA Biologics Amid Allegations

Introduction In a significant move for shareholders, the Rosen Law Firm, a leading global firm advocating for investor rights, has launched an investigation concerning potential securities claims related to ADMA Biologics, Inc. (NASDAQ: ADMA). This investigation is particularly crucial due to allegations that ADMA Biologics may have disseminated materially misleading business information, impacting its stock value and investor decisions. ## Background on the Allegations The investigation was propelled by revelations from an article published by Investing.com on March 24, 2026, which reported drastic shifts in ADMA Biologics' stock prices. According to the article, ADMA Biologics experienced a concerning 16.6% decline on the same day following a report from short seller Culper Research. This report accused the company of engaging in potentially unlawful practices, notably 'channel stuffing' to artificially inflate its revenue growth. Channel stuffing is a practice where companies ship more products to distributors than they can sell, thereby creating a misleading picture of higher revenue. The implications of such allegations are severe, as they not only affect investor trust but also pose significant legal challenges for the firm. ## What This Means for Investors Investors who purchased shares of ADMA Biologics during the relevant period may be eligible for compensation without incurring any out-of-pocket expenses through a contingency fee arrangement with the Rosen Law Firm. This means that the firm undertakes the financial risk, allowing affected shareholders to seek recovery for their losses without the burden of upfront legal fees. For those interested in joining the prospective class action, comprehensive details and assistance are available by visiting the Rosen Law Firm's website or directly contacting Phillip Kim, Esq., who is spearheading this initiative. ## The Importance of Choosing the Right Legal Counsel Selecting competent legal representation is pivotal for investors, especially in complex securities litigation. The Rosen Law Firm emphasizes the importance of opting for counsel that is not only experienced but also has a proven track record in managing securities class actions. Many firms may lack the necessary resources or expertise in this area, which could jeopardize the potential recovery for investors. The Rosen Law Firm has established itself as a leader in this field, having achieved several notable settlements in securities class actions, including the largest settlement against a Chinese company to date. Their history of success is complemented by recognitions from ISS Securities Class Action Services, ranking them consistently in the top tiers for securities class action settlements over the years, showcasing their expertise and dedication to representing investors globally. ## Encouragement to Join Class Action ADMA Biologics' investors are encouraged not to delay in taking action. Joining the class action can provide substantial benefits, including the potential for financial relief. The legal landscape can be daunting, but with experienced advocates like the Rosen Law Firm, investors can navigate their options with greater confidence. For continued updates and information, stakeholders can follow the Rosen Law Firm across social media platforms, including LinkedIn, Twitter, and Facebook. Being informed is crucial as developments unfold in this case. ## Conclusion As the investigation progresses, ADMA Biologics' shareholders should remain vigilant and consider their legal options carefully. The Rosen Law Firm's commitment to representing investor rights underscores the importance of corporate accountability and transparency in the financial markets. Investors deserve to make informed decisions based on accurate and truthful information, and with the support of experienced counsel, they can seek justice and financial recovery. If you believe you have been impacted by these developments with ADMA Biologics, now may be the critical time to reach out and explore possible avenues for recourse.